Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate CancerSeptember 11th 2014
Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.
Latest Evidence Guides Use of ADT with RT in Prostate CancerSeptember 4th 2014
Practice-changing trends in the combined use of androgen deprivation therapy (ADT) and radiation therapy (RT) for the treatment of prostate cancer were highlighted recently in a review paper by Mack Roach III, MD, a professor of Radiation Oncology and Urology and chair of the Department of Radiation Oncology at the University of California, San Francisco.
Enzalutamide + Sipuleucel-T Gives Immune Boost in mCRPCSeptember 1st 2014
Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.
Sipuleucel-T Helps ADT Boost Prostate Cancer ImmunityAugust 28th 2014
Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.